SCHEMBL385127

SCHEMBL385127

NCC(=O)NCCC(=O)O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ECE1 P42892 4/20 0.58
GABRR1 P24046 2/20 0.44
GLRA1 P23415 1/20 0.43
SLC6A9 P48067 1/20 0.43
OR51E2 Q9H255 1/20 0.43
KDM4E B2RXH2 4/20 0.42
KDM5C P41229 3/20 0.42
PHF8 Q9UPP1 3/20 0.42
KDM2A Q9Y2K7 3/20 0.42
ITGB3 P05106 2/20 0.41
ITGA2B P08514 2/20 0.41
TSHR P16473 2/20 0.40
GABRR3 A8MPY1 1/20 0.40
GABRP O00591 1/20 0.40
GABRD O14764 1/20 0.40
HDAC3 O15379 1/20 0.40
GABBR2 O75899 1/20 0.40
LMNA P02545 1/20 0.40
CYP1A2 P05177 1/20 0.40
THRB P10828 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oxalic Acid SCHEMBL28780170 0.93 ECE1 (0.52) ECE1GABRR1GLRA1SLC6A9OR51E2
SCHEMBL13631859 0.91 ECE1 (0.50) ECE1GABRR1GLRA1SLC6A9OR51E2
SCHEMBL264486 0.91 ECE1 (0.50) ECE1GABRR1GLRA1SLC6A9OR51E2
SCHEMBL1706510 0.86 ATM (0.52) ECE1GABRR1KDM4ETSHRGABRR3
SCHEMBL19520656 0.84 PRMT1 (0.59) GABRR1ITGB3ITGA2BTSHRGABRR3
SCHEMBL2897506 0.83 ECE1 (0.56) ECE1GABRR1KDM4EKDM5CPHF8
SCHEMBL8519057 0.82 PRMT1 (0.63) ITGB3ITGA2BTSHRLMNATHRB
SCHEMBL7436387 0.82 PRMT1 (0.63) ITGB3ITGA2BTSHRLMNATHRB
SCHEMBL9717431 0.81 ECE1 (0.65) ECE1KDM4EKDM5CPHF8KDM2A
SCHEMBL9717468 0.81 ECE1 (0.81) ECE1KDM4EKDM5CPHF8KDM2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240002435-A1 SYNTHETIC PEPTIDE AND APPLICATION THEREOF WUHAN INNERSE PHARMACEUTICAL INC. (CN) 2024-01-04 US claimed
WO-2022188877-A1 SYNTHETIC PEPTIDE AND APPLICATION THEREOF 武汉英纳氏药业有限公司 2022-09-15 WO claimed
CN-1036832-C Composition containing a penem or carbapenem artibiotic and the use of the same SANKYO CO (JP) 1997-12-31 CN claimed
EP-0226304-B1 COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC SANKYO COMPANY LIMITED (JP) 1991-08-28 EP claimed
US-4757066-A Reduces renal toxicity SANKYO COMPANY LIMITED (JP) 1988-07-12 US claimed
EP-0226304-A1 Composition containing a penem or carbapenem antibiotic SANKYO COMPANY LIMITED (JP) 1987-06-24 EP claimed
CN-86107574-A Compositions containing penem or carbapenem antibiotics and their use 1987-05-20 CN claimed
CN-115531366-A Method of treating multiple sclerosis 渤健马萨诸塞州股份有限公司 2022-12-30 CN disclosed
CN-115501218-A Methods of treating multiple sclerosis 渤健马萨诸塞州股份有限公司 2022-12-23 CN disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
WO-2022188877-A1 SYNTHETIC PEPTIDE AND APPLICATION THEREOF 武汉英纳氏药业有限公司 2022-09-15 WO disclosed
US-11427615-B2 Peptide compound and application thereof, and composition containing peptide compound XDCEXPLORER (SHANGHAI) CO., LTD. (CN) 2022-08-30 US disclosed
CN-114146079-A Pharmaceutical composition containing dimethyl fumarate 比奥根玛公司 2022-03-08 CN disclosed
EP-0882768-A2 Method for producing of phthalocyanine compound NIPPON SHOKUBAI CO., LTD. (JP) 1998-12-09 EP disclosed
CN-1036832-C Composition containing a penem or carbapenem artibiotic and the use of the same SANKYO CO (JP) 1997-12-31 CN disclosed
EP-0226304-B1 COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC SANKYO COMPANY LIMITED (JP) 1991-08-28 EP disclosed
EP-0384362-A2 Glycinderivatives F. HOFFMANN-LA ROCHE AG (CH) 1990-08-29 EP disclosed
US-4757066-A Reduces renal toxicity SANKYO COMPANY LIMITED (JP) 1988-07-12 US disclosed
EP-0226304-A1 Composition containing a penem or carbapenem antibiotic SANKYO COMPANY LIMITED (JP) 1987-06-24 EP disclosed
CN-86107574-A Compositions containing penem or carbapenem antibiotics and their use 1987-05-20 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11427615-B2 Peptide compound and application thereof, and composition containing peptide compound KISS1R, VIP, NPY1R ECE1 728/4885GABRR1 853/4885GLRA1 1155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.